A novel mutation in the lysyl hydroxylase 1 gene causes decreased lysyl hydroxylase activity in an ehlers-danlos VIA patient

Creative Commons License

Walker L. C., Overstreet M. A., Siddiqui A., De Paepe A., CEYLANER G., Malfait F., ...More

Journal of Investigative Dermatology, vol.124, no.5, pp.914-918, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 124 Issue: 5
  • Publication Date: 2005
  • Doi Number: 10.1111/j.0022-202x.2005.23727.x
  • Journal Name: Journal of Investigative Dermatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.914-918
  • Keywords: collagen cross-linking, collagen disorders, collagen hydroxylation, human skin fibroblasts, mutation analysis, EXPRESSION, DEFICIENCY, TISSUE
  • Lokman Hekim University Affiliated: No


The clinical diagnosis of a patient with the phenotype of Ehlers-Danlos syndrome type VI was confirmed biochemically by the severely diminished level of lysyl hydroxylase (LH) activity in the patient's skin fibroblasts. A novel homozygous mutation, a single base change of T1360 → G in exon 13 of the LH1 gene, predicted to result in W446G, was identified in the patient's full-length cDNA. This was confirmed in genomic DNA from both the patient and her parents, who were heterozygous for the mutation. This mutation was introduced into an LH1-pAcGP67 baculoviral construct and expressed, in parallel with normal LH1, in an insect cell system. The loss of LH activity in the mutated recombinant construct confirmed the pathogenicity of this mutation. Although not in the major catalytic site, this mutation occurs in a highly conserved region of the LH1 gene and may contribute to loss of activity by interfering with normal folding of the enzyme. Copyright © 2005 by The Society for Investigative Dermatology, Inc.